Here we report that although EGFR/ERK pathway inhibition initially attenuates tumor progression and induces tumor regression, it is uniformly limited by an acquired drug resistance, and subsequent failure to sustain either tumor regression or stability. Here, MAPK1 is linked to neoplasm.